Skip to content
2000
image of Rhabdomyolysis Following Trimethoprim-Sulfamethoxazole Therapy: A Case Report and Review of the Literature

Abstract

Background

Trimethoprim-Sulfamethoxazole (TMP-SMX) is a commonly used antibiotic for the treatment of several infections, such as urinary tract infections, respiratory infections, and in certain cases, septic arthritis. Rhabdomyolysis (RM) is very rare and less than 20 cases have been reported, so far, in the literature, in particular in immunocompromised patients. Here, we report a case of TMP-SMX-induced RM in an immunocompetent patient, adding to the limited data on this association.

Case Presentation

A 53-year-old male patient with no prior medical history presented with septic arthritis and was initiated on TMP-SMX therapy. Within days, he developed muscle pain and weakness with laboratory tests revealing markedly elevated Creatine Kinase (CK) levels, consistent with rhabdomyolysis. Following the discontinuation of TMP-SMX, the patient’s CK levels gradually decreased, and his symptoms resolved without further intervention.

Conclusion

To our knowledge, this is the sixth reported case of TMP-SMX-associated rhabdomyolysis in an immunocompetent patient. This case highlights the need for clinicians to consider the potential for rhabdomyolysis in patients receiving TMP-SMX, regardless of their immune status, and to recognize that prompt withdrawal of the drug is critical for patient recovery.

Loading

Article metrics loading...

/content/journals/cds/10.2174/0115748863336905241227074501
2025-01-29
2025-09-01
Loading full text...

Full text loading...

References

  1. Hindosh N. Kotala R. Nguyen K. Pintor A. Trimethoprim-sulfamethoxazole-induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) complicated by acute liver failure. Cureus 2022 14 10 e30852 10.7759/cureus.30852 36457619
    [Google Scholar]
  2. Sperandeo M. Pantic D. Army J. Acute toxin-mediated rhabdomyolysis during treatment with trimethoprim-sulfamethoxazole. Clin. Pract. Cases Emerg. Med. 2019 3 4 357 360 10.5811/cpcem.2019.7.42688 31763587
    [Google Scholar]
  3. WHO-UMC. The use of the WHO-UMC system for standardised case causality assessment. 2010 Available from: http://who-umc.org/Graphics/24734.pdf [Last accessed on 2024 nov 6].
  4. Naranjo C.A. Busto U. Sellers E.M. Sandor P. Ruiz I. Roberts E.A. Janecek E. Domecq C. Greenblatt D.J. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981 30 2 239 245 10.1038/clpt.1981.154 7249508
    [Google Scholar]
  5. Ainapurapu B. Kanakadandi U.B. Trimethoprim-sulfamethoxazole induced rhabdomyolysis. Am. J. Ther. 2014 21 3 e78 e79 10.1097/MJT.0b013e31824567fe 23689093
    [Google Scholar]
  6. Kiel P.J. Dickmeyer N. Schwartz J.E. Trimethoprim-sulfamethoxazole-induced rhabdomyolysis in an allogeneic stem cell transplant patient. Transpl. Infect. Dis. 2010 12 5 451 454 10.1111/j.1399‑3062.2010.00524.x 20561303
    [Google Scholar]
  7. Petrov M. Yatsynovich Y. Lionte C. An unusual cause of rhabdomyolysis in emergency setting: Challenges of diagnosis. Am. J. Emerg. Med. 2015 33 1 123.e1 123.e3 10.1016/j.ajem.2014.05.041 24997105
    [Google Scholar]
  8. Jen S.P. Sharma R. Trimethoprim-sulphamethoxazole-associated rhabdomyolysis in an HIV-infected patient. Int. J. STD AIDS 2011 22 7 411 412 10.1258/ijsa.2009.009516 21729964
    [Google Scholar]
  9. Goyal H. Hang M. Singla U. Chiranjeevi S. Trimethoprim-sulfamethoxazole associated rhabdomyolysis in an immunocompetent patient: Case report and review of the literature. J. Lab. Precis. Med. 2017 2 85 85 10.21037/jlpm.2017.10.01
    [Google Scholar]
  10. Moye P.M. Manasen S. O’Brien K. Sulfamethoxazole-trimethoprim-induced rhabdomyolysis in an immunocompetent patient: A case report. Case Reports in Clinical Medicine 2017 6 12 311 316 10.4236/crcm.2017.612037
    [Google Scholar]
  11. Augustyn A. Lisa Alattar M. Naina H. Rhabdomyolysis due to trimethoprim-sulfamethoxazole administration following a hematopoietic stem cell transplant. Case Rep. Oncol. Med. 2015 2015 1 4 10.1155/2015/619473 26557399
    [Google Scholar]
  12. Walker S. Norwood J. Thornton C. Schaberg D. Trimethoprim-sulfamethoxazole associated rhabdomyolysis in a patient with AIDS: Case report and review of the literature. Am. J. Med. Sci. 2006 331 6 339 341 10.1097/00000441‑200606000‑00011 16775445
    [Google Scholar]
  13. Singer S.J. Racoosin J.A. Viraraghavan R. Rhabdomyolysis in human immunodeficiency virus--positive patients taking trimethoprim-sulfamethoxazole. Clin. Infect. Dis. 1998 26 1 233 234 10.1086/517073 9455569
    [Google Scholar]
  14. Wen Z. Liang Y. Hao Y. Delavan B. Huang R. Mikailov M. Tong W. Li M. Liu Z. Drug-Induced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management. Drug Discov. Today 2019 24 1 9 15 10.1016/j.drudis.2018.06.006 29902520
    [Google Scholar]
  15. Hohenegger M. Drug induced rhabdomyolysis. Curr. Opin. Pharmacol. 2012 12 3 335 339 10.1016/j.coph.2012.04.002 22560920
    [Google Scholar]
/content/journals/cds/10.2174/0115748863336905241227074501
Loading
/content/journals/cds/10.2174/0115748863336905241227074501
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test